drug
sofosbuvir
Marketedupdated 3mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying sofosbuvir
- phase4Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
- phase3C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
- phase3C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
- phase4The Kentucky Viral Hepatitis Treatment Study
- phase2Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19
- EP1Lung Transplant HCV, Pilot Study
- phase2An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
- phase1Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 28, 2026
8 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (182)
- Jul 30, 2034patentUS 10086011*PED
- Jul 30, 2034patentUS 10086011*PED
- Jul 30, 2034patentUS 11116783*PED
- Jul 30, 2034patentUS 11116783*PED
- Jul 30, 2034patentUS 11116783*PED
- Jul 30, 2034patentUS 11116783*PED
- Jul 30, 2034patentUS 11707479*PED
- Jul 30, 2034patentUS 11707479*PED
- Jul 30, 2034patentUS 9757406*PED
- Jul 30, 2034patentUS 9757406*PED
- Jan 30, 2034method-of-use (U-1470)US 10086011
- Jan 30, 2034method-of-use (U-1470)US 10086011
- Jan 30, 2034formulationUS 11116783
- Jan 30, 2034formulationUS 11116783
- Jan 30, 2034formulationUS 11116783
- Jan 30, 2034formulationUS 11116783
- Jan 30, 2034formulationUS 11707479
- Jan 30, 2034formulationUS 11707479
- Jan 30, 2034formulationUS 9757406
- Jan 30, 2034formulationUS 9757406
- May 16, 2033patentUS 8575135*PED
- May 16, 2033patentUS 8575135*PED
- May 16, 2033patentUS 8575135*PED
- May 16, 2033patentUS 8575135*PED
- May 16, 2033patentUS 8921341*PED
- May 16, 2033patentUS 8921341*PED
- May 16, 2033patentUS 8921341*PED
- May 16, 2033patentUS 8921341*PED
- May 16, 2033patentUS 8940718*PED
- May 16, 2033patentUS 8940718*PED
- May 16, 2033patentUS 8940718*PED
- May 16, 2033patentUS 8940718*PED
- Nov 16, 2032compositionUS 8575135
- Nov 16, 2032compositionUS 8575135
- Nov 16, 2032compositionUS 8575135
- Nov 16, 2032compositionUS 8575135
- Nov 16, 2032compositionUS 8921341
- Nov 16, 2032compositionUS 8921341
- Nov 16, 2032compositionUS 8921341
- Nov 16, 2032compositionUS 8921341
- Nov 16, 2032compositionUS 8940718
- Nov 16, 2032compositionUS 8940718
- Nov 16, 2032compositionUS 8940718
- Nov 16, 2032compositionUS 8940718
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Jun 11, 2031patentUS 8618076*PED4.8y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Mar 13, 2031patentUS 9284342*PED4.6y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Dec 11, 2030compositionUS 86180764.3y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 13, 2030compositionUS 92843424.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 7964580*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8633309*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 8889159*PED3.1y
- Sep 26, 2029patentUS 9549941*PED3.1y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 79645802.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029compositionUS 86333092.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029formulationUS 88891592.6y
- Mar 26, 2029method-of-use (U-1958)US 95499412.6y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8334270*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8580765*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 8735372*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Sep 21, 2028patentUS 9085573*PED2.1y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 83342701.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028compositionUS 85807651.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028method-of-use (U-1470)US 87353721.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
- Mar 21, 2028compositionUS 90855731.6y
FDA exclusivities (12)
- Dec 10, 2028PEDPediatric (6mo bonus)2.3y
- Jun 10, 2028ODE-376Orphan Drug (7y)1.8y
- Sep 19, 2027PEDPediatric (6mo bonus)1.1y
- Sep 19, 2027PEDPediatric (6mo bonus)1.1y
- Sep 19, 2027PEDPediatric (6mo bonus)1.1y
- Mar 19, 2027ODE*ODE*211d
- Mar 19, 2027ODE-293Orphan Drug (7y)211d
- Mar 19, 2027ODE-293Orphan Drug (7y)211d
- Aug 28, 2026ODE-258Orphan Drug (7y)8d
- Aug 28, 2026ODE*ODE*8d
- Aug 28, 2026ODE-258Orphan Drug (7y)8d
- Aug 28, 2026ODE*ODE*8d
News(1)
- Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialAtea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.fiercebiotech · 22d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that